Detalles de la búsqueda
1.
Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents.
Cancer Immunol Immunother
; 70(6): 1691-1704, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33388994
2.
Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients.
Angiogenesis
; 22(3): 433-440, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30977010
3.
Potential Role of Circulating PD-L1+ Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients.
Biomedicines
; 12(5)2024 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38790920
4.
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Clin Transl Oncol
; 26(7): 1779-1789, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38512450
5.
Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes.
Lung Cancer
; 183: 107318, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37557022
6.
Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents.
Front Oncol
; 10: 1677, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33014837
7.
Oligometastatic disease: a need for consensus to cure the incurable in a multidisciplinary approach.
Chin Clin Oncol
; 13(2): 28, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38199796
Resultados
1 -
7
de 7
1
Próxima >
>>